Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Yibo Xue, Brian Meehan, Zheng Qing Fu, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 158

Showing 1-25 of 158 citing articles:

The SWI/SNF complex in cancer — biology, biomarkers and therapy
Priya Mittal, Charles W.M. Roberts
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 435-448
Open Access | Times Cited: 472
Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies
Richard C. Centore, Gabriel J. Sandoval, Luis M. Soares, et al.
Trends in Genetics (2020) Vol. 36, Iss. 12, pp. 936-950
Open Access | Times Cited: 290
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao, Joyce Cheng, Erik Bloomquist, et al.
The Lancet Oncology (2019) Vol. 21, Iss. 2, pp. 250-260
Closed Access | Times Cited: 242
Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy
Marek Wanior, Andreas Krämer, Stefan Knapp, et al.
Oncogene (2021) Vol. 40, Iss. 21, pp. 3637-3654
Open Access | Times Cited: 110
CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal
Lisa Crozier, Reece Foy, Brandon L. Mouery, et al.
The EMBO Journal (2022) Vol. 41, Iss. 6
Open Access | Times Cited: 86
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer
Biagio Ricciuti, Giuseppe Lamberti, Sreekar Reddy Puchala, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. 1311-1321
Open Access | Times Cited: 41
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines
Marc Tischkowitz, Sidong Huang, Susana Banerjee, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 15, pp. 3908-3917
Open Access | Times Cited: 118
Clinicopathologic Characteristics of BRG1-Deficient NSCLC
Ibiayi Dagogo‐Jack, Alexa B. Schrock, Marina Kem, et al.
Journal of Thoracic Oncology (2020) Vol. 15, Iss. 5, pp. 766-776
Open Access | Times Cited: 105
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
Yibo Xue, Brian Meehan, Elizabeth Macdonald, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 97
SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma Are Distinct Clinicopathologic Entities
David L. Kolin, Charles M. Quick, Fei Dong, et al.
The American Journal of Surgical Pathology (2019) Vol. 44, Iss. 2, pp. 263-270
Closed Access | Times Cited: 87
Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung
Carla P. Concepcion, Sai Ma, Lindsay M. LaFave, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 562-585
Open Access | Times Cited: 74
Recurrent Loss of SMARCA4 in Sinonasal Teratocarcinosarcoma
Lisa M. Rooper, Nasir Uddin, Jeffrey Gagan, et al.
The American Journal of Surgical Pathology (2020) Vol. 44, Iss. 10, pp. 1331-1339
Closed Access | Times Cited: 72
The i-Motif as a Molecular Target: More Than a Complementary DNA Secondary Structure
Susie L. Brown, Samantha Kendrick
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 96-96
Open Access | Times Cited: 66
Recent updates in thoracic SMARCA4-deficient undifferentiated tumor
Aruna Nambirajan, Deepali Jain
Seminars in Diagnostic Pathology (2021) Vol. 38, Iss. 5, pp. 83-89
Closed Access | Times Cited: 63
A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers
Ling Peng, Jisheng Li, Jie Wu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 60
SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy
Kristina Mardinian, Jacob J. Adashek, Gregory P. Botta, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 12, pp. 2341-2351
Open Access | Times Cited: 56
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
Yumeng Tian, Lu Xu, Xin Li, et al.
Cancer Letters (2022) Vol. 554, pp. 216022-216022
Open Access | Times Cited: 52
Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways
Anthony R. Soltis, Nicholas W. Bateman, Jianfang Liu, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100819-100819
Open Access | Times Cited: 44
Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability
Xiaoyu Liu, Zhi Li, Zhongmin Wang, et al.
Cancer Research (2022) Vol. 82, Iss. 5, pp. 791-804
Open Access | Times Cited: 39
Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies
Jin Ng, Ling Cai, Luc Girard, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 9, pp. 1846-1858
Open Access | Times Cited: 25
Clinical characteristics and prognostic analysis of SMARCA4‐deficient non‐small cell lung cancer
Xiyue Liang, Xianzheng Gao, Feng Wang, et al.
Cancer Medicine (2023) Vol. 12, Iss. 13, pp. 14171-14182
Open Access | Times Cited: 23
Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go
Vito Longo, Annamaria Catino, Michele Montrone, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3237-3237
Open Access | Times Cited: 10
Chromatin remodellers as therapeutic targets
Hayden A. Malone, Charles W.M. Roberts
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 9, pp. 661-681
Closed Access | Times Cited: 10
Targeting SWI/SNF Complexes in Cancer: Pharmacological Approaches and Implications
Megan R. Dreier, Jasmine Walia, Ivana L. de la Serna
Epigenomes (2024) Vol. 8, Iss. 1, pp. 7-7
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top